MEDICAL JOURNAL Yongwen Jiang, Phd (USPS 464-820), a Monthly Publication, Is Deborah N

Total Page:16

File Type:pdf, Size:1020Kb

MEDICAL JOURNAL Yongwen Jiang, Phd (USPS 464-820), a Monthly Publication, Is Deborah N RHODE ISLAND M EDICAL J OURNAL Body Worlds Vital visits Rhode Island, page 66 R SPECIAL SECTION ADVANCES IN AUTOIMMUNE DISEASES GUEST EDITOR: EDWARD V. LALLY, MD DECember 2016 VOLUME 99 • NUMBER 12 ISSN 2327-2228 Your records are secure. Until they’re not. Data theft can happen to anyone, anytime. A misplaced mobile device can compromise your personal or patient records. RIMS IBC can get you the cyber liability insurance you need to protect yourself and your patients. Call us. 401-272-1050 IN COOPERATION WITH RIMS IBC RIMS INSURANCE BROKERAGE CORPORATION 405 PROMENADE STREET, SUITE B, PROVIDENCE RI 02908-4811 MEDICAL PROFESSIONAL/ CYBER LIABILITY PROPERTY/ CASUALTY LIFE/HEALTH/ DISABILITY RHODE ISLAND M EDICAL J OURNAL 18 Newer Treatment Strategies for Autoimmune Diseases EDWARD V. LALLY, MD GUEST EDITOR E. Lally, MD 19 Targeted Immunomodulatory Therapy: An Overview ASHLEY L. LEFEBVRE, PharmD, CDOE LAURA MCAULIFFE, PharmD: PGY2 23 Systemic Lupus Erythematosus: A. Lefebvre, PharmD A Review of the Clinical Approach to Diagnosis and Update on Current Targeted Therapies JOANNE SZCZYGIEL CUNHA, MD KATARZYNA GILEK-SEIBERT, MD J. Cunha, MD 28 Pemphigus: Pathogenesis to Treatment K. Gilek-Siebert, MD CHRISTOPHER DIMARCO, MD 32 Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): C. DiMarco, MD Clinical Features, Diagnosis, and Current Treatment Strategies JACQUES REYNOLDS, DO GEORGE SACHS, MD, PhD G. Sachs, MD, PhD KARA STavROS, MD 36 Autoimmune Cytopenias: Diagnosis & Management CHRISTIAN P. NIXON, MD, PhD JOSEPH D. SWEENEY, MD C. Nixon, MD, PhD RHODE ISLAND M EDICAL J OURNAL 8 COMMENTARY Medical Tourism JOSEPH H. FRIEDMAN, MD Dickensian Diagnostics: The Diseases of Christmas Past What ailed Scrooge and Tiny Tim? HERBERT RAKATANSKY, MD Reconnecting with my Purpose in the Kingdom of Bhutan ERIC COHEN, MD 17 RIMJ AROUND THE WORLD New York, New York 58 RIMS NEWS Are you reading RIMS Notes? Working for You Weight + Wellness Summit Why You Should Join RIMS 66 SPOTLIGHT Body Worlds Exhibit: Anatomy Up Close & Personal MARY KORR 78 HeritaGE Dec. 7, 1941: 75 years ago, Japan attacks Pearl Harbor RIMJ launches special features: Doctors at War & Calling All Battle Stations MARY KORR RHODE ISLAND M EDICAL J OURNAL IN THE NEWS ALPERT FOUNDATION 68 72 WOMEN & INFANTS awards Brown medical school $27M files letter of intent for renovation of labor and delivery suite AMA ADOPTS NEW POLICIES 68 to support student wellness and mental health 72 STOICO/FIRSTFED FOUNDATION TEXTBOOK 70 donates $1.1M for maternity care trains physicians on ‘third science’ at St. Luke’s Hospital BRADLEY HASBRO CHILDREN’S RESEARCH CENTER 70 73 DRS. GRUPPUSO, ADASHI awarded $3.3M NIH grant to study effects of trauma question ‘residency placement fever’ on teens and value of social media in recovery PEOPLE/PLACES PHYLLIS A. DENNERY, MD 75 76 ROGER WILLIAMS CANCER CENTER named president-elect recognized at American Cancer of Society for Redox Society’s RI research breakfast Biology and Medicine 78 GAURAV GUPTA, MD, DEMETRA C. OUELLETTE 75 graduates from AAO leadership named president of Roger development program Williams Medical Center 78 MEMORIAL HOSPITAL LAWRENCE T. SAULNIER, RN, BSN 75 School of Nurse Anesthesia joins Visiting Nurse of HopeHealth graduates 9 as director of nursing 80 ROBERT J. WESTLAKE, MD, EDEN CARDOZO, MD 76 honored by Butler Hospital joins W&I to oversee fertility preservation 80 KENT’S WOMEN’S CARE CENTER program receives Baby-Friendly designation DECEMBER 2016 VOLUME 99 • NUMBER 12 RHODE ISLAND Rhode Island Medical Society R I Med J (2013) 2327-2228 M EDICAL J OURNAL 99 PUBLISHER RHODE ISLAND MEDICAL SOCIETY 12 PRESIDENT 2016 RUSSELL A. SETTIpane, MD December PRESIDENT-ELECT 1 SARAH J. FESSLER, MD VICE PRESIDENT BRADLEY J. COLLINS, MD CONTRIBUTION secretary CHRISTINE BROUSSEEAU, MD 41 Fibromyalgia Syndrome, A Geriatric Challenge TREASURER JULIO C. DEFILLO-DRAIBY, MD JOSE R. POLANCO, MD JOHN S. PAGE IMMEDiate PAST PRESIDENT PETER KARCZMAR, MD EXECUTIVE DIRECTOR CASE REPORTS NEWELL E. WARDE, PhD 45 Fournier’s gangrene of the penis in a EDITOR-IN-CHIEF 12-year-old patient secondary to phimosis JOSEPH H. FRIEDMAN, MD LUTHER WaRD, MD, MPH, FACS associate EDITOR DANIEL EISENSON, BA SUN HO AHN, MD JEAN-LOUIS FILS, MD PUBLication StaFF MANAGING EDITOR 47 Right in Front of Our Eyes: MARY KORR Evolution of Streptococcal Toxic Shock Syndrome [email protected] with Ischemic Optic Neuropathy GRAPHIC DESIGNER SALAHELDIN M. ELHAMAMSY, MD MARIANNE MIGLIORI MAZEN O. AL-QADI, MD ADVertisinG STEVEN DETOY TaRO MINAMI, MD SARAH STEVENS MARGUERITE NEILL, MD [email protected] EDITORIAL BOARD PUBLIC HEALTH JOHN J. CRONAN, MD JAMES P. CROWLEY, MD 50 PUBLIC HEALTH BRIEFING EDWARD R. FELLER, MD Ten Years and Growing: JOHN P. FULTON, PhD PETER A. HOLLMANN, MD Medical Marijuana in Rhode Island – Where Are We Now? KENNETH S. KORR, MD JAMES V. MCDONALD, MD, MPH MARGUERITE A. NEILL, MD MIKE SIMOLI FRANK J. SCHABERG, JR., MD LAWRENCE W. VERNAGLIA, JD, MPH 53 HEALTH BY NUMBERS NEWELL E. WaRDE, PhD Surveillance of Suicide and Suicide Attempts Among Rhode Island Youth Using Multiple Data Sources RHODE ISLAND MEDICAL JOURNAL YONGWEN JIANG, PhD (USPS 464-820), a monthly publication, is DEBORAH N. PEARLMAN, PhD owned and published by the Rhode Island JEFFREY HILL, MS Medical Society, 405 Promenade Street, Suite A, Providence RI 02908, 401-331-3207. All SAMARA VINER-BROWN, MS rights reserved. ISSN 2327-2228. Published articles represent opinions of the authors and 57 Vital Statistics do not necessarily reflect the official policy of the Rhode Island Medical Society, unless ROSEANN GIORGIANNI, DEPUTY STATE REGISTRAR clearly specified. Advertisements do not im- ply sponsorship or endorsement by the Rhode Island Medical Society. Advertisers contact: Sarah Stevens, RI Medical Society, 401-331-3207, fax 401-751-8050, [email protected]. © COPYRIGHT JANUARY 2013, RHODE ISLAND MEDICAL SOCIETY, ALL RIGHTS RESERVED. Increase your Risk IQ Outsmarting risk requires a high degree of intelligence – yours and ours. Changing care delivery models, new technology, and shifting responsibilities create new exposures for physicians and hospitals daily. But with the right risk intelligence, you can predict and prevent those vulnerabilities. Coverys combines proven Medical Professional Liability Insurance with proactive risk analytics, resources, and education to outsmart risk and improve outcomes. Visit Coverys.com or call 800-225-6168 ProSelect Insurance Company commentary Medical Tourism JOSEPH H. FRIEDMAN, MD [email protected] 8 9 EN THIS COLUMN IS ABOUT A I am monolingual, which might be wise advice for any different sort of medi- a major drawback, I teacher, especially one from New York. cal tourism. The term believe, in life. I find There are two questions to consider “medical tourism” gen- the experiences always about this type of medical tourism. erally refers to patients enriching. Now that I am What are the benefits for the tourist and who travel outside their an experienced, old-hand what are the benefits for the recipient? country to seek medical at this, or, simply, just The hosts always act grateful, although, care, usually because of old, and a professor at to be honest, cultural insensitivity expense. There are places Brown, I have taken on from both ends, may undercut this. that may be tourist des- the title of the visiting My colleagues at home rarely appear to tinations, with nice cli- professor. Since I have comprehend, however, how much the mates, beautiful beaches, visited places that are tourist receives in exchange. cheap hotels and good food, where the greatly deficient in neurology, I think Each medical trip I’ve made has staff may be first rate, often Ameri- I can make a difference, albeit a small always increased my gratefulness for can- or European-trained, who practice one, in helping general internists under- being born when and where I was, for medicine at a high level, with excellent stand and evaluate neurological prob- not being poor, for not having limited nursing care, air-conditioned, hotel-like lems better. There is, of course, a limit possibilities. But I’ve always been premises, and solicitous VIP treatment. on how much one can accomplish in any impressed with the resourcefulness of The cost may be less than the co-pay period of time, and shorter, obviously, the local doctors, and for the patients’ for some insurance plans, or the treat- means less. However, some government tolerance of their limited medical pos- ment may not be covered by insurance ministries are loath to consider an ex- sibilities. It is a harsh and awful fact in the U.S. or may be performed much patriot for a stay of less than 2 or 3 that a family in most of Africa will sooner than can be provided by national months, assuming, correctly, I think, in accept as an unfortunate fate that they insurers, as in Canada or England. most cases, that it takes several weeks for lack the money to pay for the tests or I have been a different kind of med- a newcomer to get his “sea legs.” It often treatment for a loved one. It contrasts ical tourist. I spent time in Tanzania takes some weeks to both understand with the railing against the unfairness of (3 months as a graduating medical English with a novel accent, especially fate I sometimes see from the children student), working in or teaching in when spoken softly, as is the norm in of the 88-year-old person with one of hospitals in Zambia (4 weeks), Kenya some places, and, perhaps more impor- the dread neurological disorders of the (2 weeks), Rwanda (10 weeks), Malawi tantly for a teacher, to be understood. elderly. Seeing medicine in different (4 weeks) and Ghana (2 weeks). I cannot When I was a Peace Corps teacher cultures teaches us about life, how each account for my focus on African coun- in Ghana, several decades ago, I some- of us lives our lives as constrained by tries, other than, perhaps, the fact that times would translate from English our cultures.
Recommended publications
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Report, Please Call the Telephone Number Listed
    201R1e port M E D I C I N E S I N D E V E L O P M E N T F O R Arthritis P R E S E N T E D B Y A M E R I C A ’ S B I O P H A R M A C E U T I C A L R E S E A R C H C O M P A N I E S Biopharmaceutical Research Companies are Developing Nearly 200 Medicines for the Most Common Chronic Health Problem in the United States merica’s biopharmaceutical research companies are MEDICINES AND VACCINES IN DEVELOPMENT FOR ARTHRITIS* currently developing 198 medicines to help the Behcet’s Syndrome 3 more than 50 million Americans afflicted with at A Duchenne Muscular Dystrophy 6 least one of the 100 different musculoskeletal disorders, Fibromyalgia 9 including arthritis. All of the medicines are either in Gout 7 clinical trials or awaiting review by the U.S. Food and Lupus 19 Muscle Disorders 11 Drug Administration. Osteoarthritis 19 Osteoporosis 23 Arthritis is the most common cause of disability in the Pain 15 United States. Each year, it is responsible for 44 million Psoriatic Arthritis 7 outpatient doctor visits, nearly 1 million hospitalizations, Raynaud’s Disease 4 and nearly 10,000 deaths. And it costs the American Rheumatoid Arthritis 67 Scleroderma 6 economy nearly $128 billion annually in direct medical Spondylitis 7 costs and indirect costs, such as lost wages and Other 22 productivity. * Some medicines are listed in more than one category.
    [Show full text]
  • The Role of Tumor Necrosis Factor Alpha (TNF-)
    International Journal of Molecular Sciences Review The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics Dan-in Jang 1,†, A-Hyeon Lee 1,† , Hye-Yoon Shin 2, Hyo-Ryeong Song 1,3 , Jong-Hwi Park 1, Tae-Bong Kang 4 , Sang-Ryong Lee 5,* and Seung-Hoon Yang 1,* 1 Department of Medical Biotechnology, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea; [email protected] (D.-i.J.); [email protected] (A.-H.L.); [email protected] (H.-R.S.); [email protected] (J.-H.P.) 2 School of Life Science, Handong Global University, Pohang, Gyeongbuk 37554, Korea; [email protected] 3 Department of Pharmacy, College of Pharmacy, Yonsei University, Seoul 03722, Korea 4 Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Korea; [email protected] 5 Department of Biological Environmental Science, Collage of Life Science and Biotechnology, Dongguk University, Seoul 04620, Korea * Correspondence: [email protected] (S.-R.L.); [email protected] (S.-H.Y.) † These authors contributed equally to this work. Abstract: Tumor necrosis factor alpha (TNF-α) was initially recognized as a factor that causes the Citation: Jang, D.-i.; Lee, A-H.; Shin, necrosis of tumors, but it has been recently identified to have additional important functions as a H.-Y.; Song, H.-R.; Park, J.-H.; Kang, pathological component of autoimmune diseases. TNF-α binds to two different receptors, which T.-B.; Lee, S.-R.; Yang, S.-H. The Role initiate signal transduction pathways.
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Ep 3178848 A1
    (19) TZZ¥__T (11) EP 3 178 848 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.06.2017 Bulletin 2017/24 C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) Application number: 15198715.3 (22) Date of filing: 09.12.2015 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Cueni, Leah Noëmi et al Designated Extension States: F. Hoffmann-La Roche AG BA ME Patent Department Designated Validation States: Grenzacherstrasse 124 MA MD 4070 Basel (CH) (71) Applicant: F. Hoffmann-La Roche AG 4070 Basel (CH) (54) TYPE II ANTI-CD20 ANTIBODY FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES (57) The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent comprising administration of a Type II anti-CD20 antibody, e.g. obinutuzumab, to the subject prior to administration of the therapeutic agent. EP 3 178 848 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 178 848 A1 Description Field of the Invention 5 [0001] The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent.
    [Show full text]
  • Rheumatoid Arthritis Market to 2020 - a Crowded Market Characterized by Modest Growth
    THERAPY ANALYSIS Rheumatoid Arthritis Market to 2020 - A Crowded Market Characterized by Modest Growth Published: December 2014 Report Code: GBIHC354MR www.gbiresearch.com GBI Research Report Guidance The report begins with an executive summary detailing the key points driving the RA market in eight key developed markets: the US, the UK, Canada, France, Germany, Spain, Italy and Japan. Chapter two provides an introduction to RA, detailing the etiology, epidemiology, diagnostic techniques, disease staging and typical prognoses for patients. An analysis of current treatment algorithms and options is also included. Chapter three offers detailed analysis of the drugs currently marketed for this indication: MTX, Remicade, Humira, Enbrel, Rituxan, Orencia, Simponi Cimzia and Xeljanz. It includes key characteristics, covering safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, historical sales, prices and overall competitive strength. These products are also compared in a comprehensive heat map. Chapter four provides detailed analysis of the pipeline for RA, by stage of development, molecule type, program type, mechanism of action and molecular target. It also analyzes recent clinical trials in this indication, by enrollment, duration and failure rate. Finally, promising late- stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength. Chapter five analyzes the clinical trials conducted since 2006 in this indication, by enrollment, duration and failure rate. Promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength. Chapter six supplies forecasts for the RA market, including epidemiology, treatment use patterns, pricing, and market size, for the 2013–2020 period. The markets are covered and data are presented at a country level with further analysis of key market drivers and barriers.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Standards, Perspektiven Und Grenzen Der Konservativen Therapie
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2013 Review: new anti-cytokines for IBD: what is in the pipeline? Scharl, Michael ; Vavricka, Stephan R ; Rogler, Gerhard Abstract: Significant advances have been achieved in the understanding of the pathogenesis ofinflam- matory bowel disease (IBD). A number of susceptibility genes have been detected by large genome wide screening-approaches. New therapeutic concepts emerge from these insights. The most important progress in recent years certainly is the introduction of biologics in the therapy of IBD. TNF blockers have been shown to be very effective for the control of complicated disease courses. Currently, in addition to the three already established anti-TNF antibodies, new anti-TNF molecules, for example Golimumab, are in clinical trials and also reveal promising results. However, not all of the patients respond to anti- TNF treatment and many patients lose their response. Therefore, additional therapeutic approaches are urgently needed. Attractive therapy targets are cytokines as well as their receptors and signaling pathways. At the moment a large number of biologicals and inhibitors are tested in clinical trials and some of them provide very promising results for the treatment of IBD patients. In particular, inhibition of IL-12p40 by specific antibodies as well as of the janus kinase (JAK)3 by a small molecule promiseto be very effective approaches. Though antibodies targeting for example IL-6, IL-6R, IL-13 orCCR9are only in the early steps of clinical development, they have already demonstrated to be a possible treatment option which needs to be confirmed in further trials.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]